• Fulfilling


    With the Science of Enzymes

  • Fulfilling


    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping


    Fulfill Their Potential

News & Media

Alcresta Therapeutics Announces RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Jun 18, 2018

WARREN, N.J. – June 18, 2018 – Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.  The code, Q9994, is effective July 1, 2018.  CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.

Alcresta Therapeutics, Inc. Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB®

Nov 06, 2017

Four additional studies with RELiZORB were presented by investigators at leading cystic fibrosis centers

Alcresta Therapeutics Receives New Innovative Technology Contract from Vizient, Inc. For RELiZORB® (iMMOBILIZED LIPASE) Cartridge

Sep 20, 2017

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. announced RELiZORB has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The awarded contract, effective Sept. 1, 2017, was based on a recommendation of RELiZORB by hospital members who serve on one of Vizient’s member-led councils.